Rifampicin as Adjunct to Colistin Therapy in the Treatment of Multidrug-Resistant Acinetobacter baumannii

Annals of Pharmacotherapy

Volumn 48, Issue 6, 2014, Pages 766-771

  Al Shaer, Mohammad ^a,b   Nazer, Lama H ^a   Kherallah, Mazen ^c  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b HAMAD MEDICAL CORPORATION   (Qatar)

^c Sanford Health System   (United States)

Author keywords

Acinetobacter baumannii; colistin; combination; drug resistant; rifampicin; treatment

Indexed keywords

CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; COLISTIN; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADJUVANT THERAPY; ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FUNCTION; LENGTH OF STAY; LIVER FUNCTION; LIVER TOXICITY; LUNG LAVAGE; MORTALITY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; ACINETOBACTER INFECTIONS; ANIMAL; DRUG COMBINATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; RIFAMPIN;

EID: 84899750775     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014528306     Document Type: Review

References (23)

1. Munoz-Price LS,Weinstein RA.Acinetobacter infection.N Engl J Med. 2008;358:1271-1281.
2. Michalopoulos A,Falagas ME.Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010;11:779-788.
3. Pogue JM,Mann T,Barber KE,Kaye KS.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.Expert Rev Anti Infect Ther. 2013;11:383-393.
4. Munoz-Price LS,Arhear K,Nordmann P,et al.Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital.Crit Care Med. 2013;41:2733-2742.
5. Imberti R,Cusato M,Villani P,et al.Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration.Chest. 2010;138:1333-1339.
6. Bergen PJ,Li J,Nation RL.Dosing of colistin-back to basic PK/PD.Curr Opin Pharmacol. 2011;11:464-469.
7. Vaara M.Agents that increase the permeability of the outer membrane.Microbiol Rev. 1992;56:395-411.
8. Savage PB.Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria.Ann Med. 2001;33:167-171.
9. Tripodi MF,Durante-Mangoni E,Fortunato R,Utili R,Zarrilli R.Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multi-drug resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.Int J Antimicrob Agents. 2007;30:537-540.
10. Song JY,Kee SY,Hwang IS,et al.In vitro activities of carbapenem/sulbactam combination, colistin/rifampicin combination and tigecycline against carbapenem-resistant.Acinetobacter baumannii. J Antimicrob Chemother. 2007;60:317-322.
11. Pantopoulou A,Giamerellos-Bourboulis EJ,Raftogannis M,et al.Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.Int J Antimicrob Agents. 2007;29:51-55.
12. Song JY,Cheong HJ,Lee J,Sung AK,Kim WJ.Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.Int J Antimicrob Agents. 2009;33:33-39.
13. Panchon-Ibanez ME,Docobo-Perez F,Lopez-Rojas R,et al.Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant.Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:1165-1172.
14. Lee JH,Bergen PJ,Bulitta JB,et al.Synergistic activity of colistin and rifampicin combination against multi-drug resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Antimicrob Agents Chemother. 2013;57:3738-3745.
15. Rodriguez CH,Ambrosio A,Bajuk M,et al.In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones.J Infect Dev Ctries. 2010;4:164-167.
16. Petrosillo N,Chinello P,Proietti MF,et al.Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.Clin Microbiol Infect. 2005;11:682-683.
17. Motaouakkil S,Charra B,Hachimi A,et al.Colistin and rifampicin in the treatment of nosocomial infections from multiresistant.Acinetobacter baumannii. J Infect. 2006;53:274-278.
18. Bassetti M,Repetto E,Righi E,et al.Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.J Antimicrob Chemother. 2008;61:417-420.
19. Song JY,Lee J,Heo JY,et al.Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem resistant.Acinetobacter baumannii. Int J Antimicrob Agents. 2008;32:281-283.
20. Simsek F,Gedik H,Yildirmak MT,et al.Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?.Indian J Med Microbiol. 2012;30:448-452.
21. Aydemir H,Akduman D,Piskin N,et al.Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.Epidemiol Infect. 2013;141:1214-1222.
22. Durante-Mangoni E,Signoriello G,Andini R,et al.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Clin Infect Dis. 2013;57:349-358.
23. Ahern JW,Schnoor JB.Colistin: potential for dosage error.Clin Infect Dis. 2012;55:1275.